Generation Bio (NASDAQ:GBIO) Rating Reiterated by Wedbush

Generation Bio (NASDAQ:GBIO)‘s stock had its “outperform” rating reaffirmed by Wedbush in a research note issued on Tuesday, Marketbeat.com reports. They currently have a $5.00 price target on the stock. Wedbush’s target price indicates a potential upside of 31.93% from the company’s current price. Wedbush also issued estimates for Generation Bio’s Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.13) EPS and Q4 2025 earnings at ($0.13) EPS.

Separately, Needham & Company LLC restated a “buy” rating and set a $10.00 target price on shares of Generation Bio in a research note on Wednesday, April 10th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Generation Bio currently has an average rating of “Hold” and a consensus price target of $8.00.

Generation Bio Trading Up 7.1 %

Shares of Generation Bio stock opened at $3.79 on Tuesday. The firm has a fifty day simple moving average of $3.35 and a 200-day simple moving average of $2.30. The stock has a market capitalization of $252.00 million, a price-to-earnings ratio of -1.49 and a beta of 2.87. Generation Bio has a 1-year low of $0.86 and a 1-year high of $6.98.

Generation Bio (NASDAQ:GBIO) last released its earnings results on Wednesday, March 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.12). The firm had revenue of $2.88 million for the quarter, compared to analyst estimates of $3.05 million. Generation Bio had a negative return on equity of 73.57% and a negative net margin of 1,696.87%. As a group, research analysts predict that Generation Bio will post -1.34 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new position in Generation Bio during the third quarter valued at about $51,000. TD Asset Management Inc raised its stake in shares of Generation Bio by 72.1% in the third quarter. TD Asset Management Inc now owns 406,598 shares of the company’s stock valued at $1,541,000 after purchasing an additional 170,343 shares in the last quarter. Kestra Private Wealth Services LLC acquired a new position in shares of Generation Bio in the fourth quarter valued at $50,000. Los Angeles Capital Management LLC boosted its stake in Generation Bio by 315.6% during the fourth quarter. Los Angeles Capital Management LLC now owns 275,834 shares of the company’s stock worth $455,000 after buying an additional 209,462 shares in the last quarter. Finally, Panagora Asset Management Inc. acquired a new stake in Generation Bio during the fourth quarter worth $49,000. Institutional investors and hedge funds own 95.22% of the company’s stock.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.